KID31 and antibodies that bind thereto
The invention provides the identification and characterization of disease and cancer-associated antigen, KID31. The invention also provides a family of monoclonal antibodies that bind to antigen KID31, methods of diagnosing and treating various human cancers and diseases that express KID31.
1. An isolated antibody produced by a host cell with a deposit number of ATCC No. PTA-6516 or progeny thereof, or an antigen-binding fragment thereof, said antibody specifically binds to carboxypeptidase M.
2. An isolated antibody that binds to carboxypeptidase M, comprising the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of the antibody produced by the cell line having ATCC No. PTA-6516.
3. The isolated antibody of claim 2 , wherein the isolated antibody is a humanized antibody.
4. The isolated antibody of claim 2 , wherein the isolated antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of the antibody produced by the cell line having ATCC No. PTA-6516.
5. The isolated antibody of claim 4 , wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
6. The isolated antibody of claim 2 , wherein the isolated antibody is linked to a therapeutic agent.
7. An antigen-binding fragment of the isolated antibody of claim 2 , wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′)2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of the antibody produced by the cell line having ATCC No. PTA-6516.
8. An isolated antibody that binds to carboxypeptidase M comprising the heavy chain variable region of the antibody produced by the cell line having ATCC No. PTA-6516.
9. An isolated antibody that binds to carboxypeptidase M comprising the light chain variable region of the antibody produced by the cell line having ATCC No. PTA-6516.
10. A pharmaceutical composition comprising the antibody of claim 2 and a pharmaceutically acceptable excipient.
11. The pharmaceutical composition of claim 10 , wherein the composition comprises an additional therapeutic moiety.
12. A pharmaceutical composition comprising the antigen-binding fragment of claim 7 and a pharmaceutically acceptable excipient.
13. A pharmaceutical composition comprising the isolated antibody of claim 8 and a pharmaceutically acceptable excipient.
14. A pharmaceutical composition comprising the isolated antibody of claim 9 and a pharmaceutically acceptable excipient.